BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $23.31
BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $23.31
BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) shares gapped down prior to trading on Tuesday . The stock had previously closed at $23.31, but opened at $22.73. BioLife Solutions shares last traded at $22.83, with a volume of 194 shares traded.
生物生命解決方案公司(納斯達克代碼：BLFS-GET Rating)的股價在週二交易前大幅下跌。該股此前收盤報23.31美元，開盤報22.73美元。BioLife Solutions的股票尾盤報22.83美元，成交量為194股。
Analyst Ratings Changes
分析師評級發生變化
A number of equities research analysts have recently issued reports on the company. B. Riley cut their target price on BioLife Solutions from $48.00 to $34.00 in a research report on Tuesday, May 17th. Cowen cut their target price on BioLife Solutions to $29.00 in a research report on Monday, August 15th. Maxim Group dropped their price target on BioLife Solutions from $60.00 to $30.00 in a research report on Thursday, May 12th. Finally, Cowen dropped their price target on BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. One analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. According to MarketBeat.com, BioLife Solutions has an average rating of "Moderate Buy" and a consensus target price of $31.25.
一些股票研究分析師最近發佈了關於該公司的報告。B.萊利在5月17日星期二的一份研究報告中將BioLife Solutions的目標價從48.00美元下調至34.00美元。考恩在8月15日星期一的一份研究報告中將BioLife Solutions的目標價下調至29.00美元。Maxim Group在5月12日星期四的一份研究報告中將BioLife Solutions的目標價從60.00美元下調至30.00美元。最後，考恩在5月10日星期二的一份研究報告中將BioLife Solutions的目標價從50.00美元下調至32.00美元。一名分析師對該股的評級為賣出，三名分析師對該股的評級為買入。根據MarketBeat.com的數據，BioLife Solutions的平均評級為“適度買入”，共識目標價為31.25美元。
BioLife Solutions Trading Up 1.9 %
BioLife Solutions股價上漲1.9%
The company has a current ratio of 3.55, a quick ratio of 2.54 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average of $19.48 and a two-hundred day moving average of $18.35.
該公司的流動比率為3.55，速動比率為2.54，債務權益比率為0.02。該公司的50日移動均線切入位為19.48美元，200日移動均線切入位為18.35美元。
Insider Buying and Selling at BioLife Solutions
BioLife Solutions的內部交易和銷售
Institutional Trading of BioLife Solutions
生物生命解決方案的制度性交易
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of BioLife Solutions by 1.6% during the 1st quarter. BlackRock Inc. now owns 3,712,680 shares of the medical equipment provider's stock worth $84,390,000 after acquiring an additional 57,623 shares in the last quarter. Vanguard Group Inc. boosted its stake in BioLife Solutions by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 2,201,602 shares of the medical equipment provider's stock valued at $50,043,000 after purchasing an additional 54,344 shares during the period. Millennium Management LLC boosted its stake in BioLife Solutions by 45.3% during the 2nd quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider's stock valued at $21,545,000 after purchasing an additional 486,631 shares during the period. Marshall Wace LLP boosted its stake in BioLife Solutions by 4.2% during the 4th quarter. Marshall Wace LLP now owns 1,346,746 shares of the medical equipment provider's stock valued at $50,193,000 after purchasing an additional 54,502 shares during the period. Finally, State Street Corp boosted its stake in BioLife Solutions by 26.1% during the 2nd quarter. State Street Corp now owns 1,270,364 shares of the medical equipment provider's stock valued at $17,544,000 after purchasing an additional 263,021 shares during the period. Institutional investors own 86.69% of the company's stock.
幾家大型投資者最近改變了他們在該股的頭寸。貝萊德股份有限公司在第一季度增持了BioLife Solutions的股份1.6%。貝萊德股份有限公司在上個季度增持了57,623股後，目前持有這家醫療設備供應商3,712,680股股票，價值84,390,000美元。先鋒集團(Vanguard Group Inc.)在第一季度增持了BioLife Solutions 2.5%的股份。先鋒集團目前持有這家醫療設備供應商2,201,602股股票，價值50,043,000美元，在此期間又購買了54,344股。千禧管理有限責任公司在第二季度將其在BioLife Solutions的股份增加了45.3%。Millennium Management LLC現在擁有這家醫療設備提供商的1,560,137股票，價值21,545,000美元，在此期間又購買了486,631股票。馬歇爾·華斯有限責任公司在第四季度將其在BioLife Solutions的持股增加了4.2%。馬歇爾·華斯有限責任公司在此期間額外購買了54,502股，現在擁有這家醫療設備提供商1,346,746股股票，價值50,193,000美元。最後，道富集團在第二季度將其在BioLife Solutions的持股增加了26.1%。道富集團目前持有這家醫療設備提供商1,270,364股股票，價值17,544,000美元，在此期間又購買了263,021股。機構投資者持有該公司86.69%的股票。
BioLife Solutions Company Profile
BioLife Solutions公司簡介
(Get Rating)
(獲取評級)
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
BioLife Solutions，Inc.為美國、加拿大、歐洲、中東、非洲和國際上的細胞和基因治療行業開發、製造和提供生物生產工具和服務。該公司的產品用於基礎和應用研究，以及基於生物的療法的商業製造。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- Broadcom Bounces From Institutional Bottom
- Affirm is the Underdog Starring in a Spaghetti Western
- Is Autozone A Buy Before Earnings Are Released?
- Is There Value in Verizon Shares at These Levels?
- MarketBeat Podcast: Stock Market, Bad News is Good News
- 免費獲取StockNews.com關於BioLife解決方案的研究報告(BLFS)
- 博通從機構底部反彈
- 阿奎姆是意大利西部片中的失敗者
- AutoZone是在收益發布之前買入的嗎？
- 在這些水平上，Verizon的股價有價值嗎？
- 市場Beat播客：股市，壞消息就是好消息
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到有關BioLife解決方案的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioLife Solutions和相關公司的最新新聞和分析師評級的每日簡要摘要。